Investors can speculate about the future of a stock by watching how its insiders buy and sell stocks. Cytokinetics Inc shares valued at $190,750 were sold by Blum Robert I on Jul 14 ’25. At $38.15 per share, Blum Robert I sold 5,000 shares. The insider’s holdings dropped to 393,108 shares worth approximately $15.21 million following the completion of this transaction.
Also, FADY MALIK purchased 14,000 shares, netting a total of over 467,040 in proceeds.
Before that, Malik Fady Ibraham had sold 2,000 shares from its account. In a trade valued at $67,520, the EVP Research & Development traded Cytokinetics Inc shares for $33.76 each. Upon closing the transaction, the insider’s holdings decreased to 2,000 shares, worth approximately $5.44 million.
As published in their initiating research note from Barclays on April 24, 2025, Cytokinetics Inc [CYTK] has been an Overweight and the price target has been revised to $55. Analysts at Citigroup started covering the stock with ‘”a Buy”‘ outlook in a report released in early February. As of January 22, 2025, Stifel has initiated its “Buy” rating for CYTK. Earlier on November 08, 2024, RBC Capital Mkts initiated its rating. Their recommendation was “an Outperform” for CYTK stock.
Analyzing CYTK Stock Performance
On last trading session,, Cytokinetics Inc [NASDAQ: CYTK] rose 1.76% to $38.68. The stock’s lowest price that day was $37.95, but it reached a high of $38.99 in the same session. During the last five days, there has been a surge of approximately 5.61%. Over the course of the year, Cytokinetics Inc shares have dropped approximately -30.90%. Shares of the company reached a 52-week high of $52.80 on 01/27/25 and a 52-week low of $29.31 on 05/15/25.
Support And Resistance Levels for Cytokinetics Inc (CYTK)
According to the 24-hour chart, there is a support level at 38.09, which, if violated, would cause prices to drop to 37.50. In the upper region, resistance lies at 39.13. The next price resistance is at 39.58. RSI (Relative Strength Index) is 68.64 on the 14-day chart, showing neutral technical sentiment.
Is Cytokinetics Inc subject to short interest?
Stocks of Cytokinetics Inc saw a sharp steep in short interest on 2025-06-13 dropping by -1.6 million shares to 14.01 million. Data from Yahoo Finance shows that the short interest on 2025-05-15 was 15.6 million shares. A decline of -11.41% in short interest reflects a positive sentiment towards the stock. Despite the fact that short shares comprise just 8.37 of the overall float, the days-to-cover ratio (short ratio) decline to 8.37.
Which companies own the most shares of Cytokinetics Inc (CYTK)?
In terms of Cytokinetics Inc share price expectations, FactSet research, analysts set an average price target of 61 in the next 12 months, up nearly 60.48% from the previous closing price of $38.01. Analysts anticipate Cytokinetics Inc stock to reach 67 by 2025, with the lowest price target being 55. In spite of this, 12 analysts ranked Cytokinetics Inc stock as Buy at the end of 2025. On August 13, 2024, Goldman assigned a price target of “a Neutral” to the stock and downgraded coverage with a $60.
